The Kinked Wire
The Society of Interventional Radiology (SIR) brings you a new podcast on all the topics that impact your practice of IR, with focused subseries reflecting the broad range of the specialty. In each episode, hosts and guests discuss new clinical opportunities, practice management tips, the latest trends and developments in the specialty, and more. Learn more on sirweb.org, irq.sirweb.org, and sirweb.org/kinkedwire. If you have any ideas for topics or guests, or have any other feedback, let us know at kinkedwire@sirweb.org. For corporate support opportunities, contact SIR at jnash@sirweb.org. The views and opinions expressed in podcast episodes are not necessarily those of the Society of Interventional Radiology. The society does not endorse any companies or products.
The Kinked Wire
Episode 26: EPOCH Trial results suggest promising treatment for metastatic colorectal cancer patients
I think this is actually a model that can in fact be propagated across multiple types of centers, as long as that communication is there. —Riad Salem, MD, MBA, FSIR, Co-principal investigator, EPOCH Trial
Warren Krackov, MD, FSIR, speaks with interventional radiologist and EPOCH Trial co-principal investigator Riad Salem, MD, MBA, FSIR, about the results of the trial and the potential for Y-90 treatment with TheraSpheres in patients with colorectal cancer metastases.
NOTE: EPOCH, an IDE pivotal trial, was a 428-patient, open-label, international, multicenter, phase 3 trial. EPOCH evaluated the safety and efficacy of TheraSphere Y-90 Glass Microspheres combined with second-line therapy (oxaliplatin- or irinotecan-based chemotherapy) in patients with mCRC of the liver. EPOCH met both primary endpoints of progression free survival and hepatic progression free survival. Learn more from Boston Scientific.
This episode was recorded on Dec. 7, 2021.
Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.
(c) Society of Interventional Radiology.